Insmed (NASDAQ:INSM) saw its share price increase by 33.86 percent on Thursday to close at $132.55 apiece after nearly quadrupling its revenues in the second quarter of the year, thanks to a strong uptake from its treatment for non-cystic fibrosis bronchiectasis (NCFB).
In an updated report, the company said that total revenues soared by 296 percent during the period to $425.5 million from only $107.4 million in the same period last year, on the back of a $309.2 million share from its drug, Brinsupri.
On the other hand, its lung disease treatment, Arikayce, contributed $116.3 million in revenues, up 8 percent from $107.4 million year-on-year.
The strong performance helped the company slash its net loss in the same period of the year by 96 percent to only $13.2 million from the $321.7 million loss in the same comparable period.
First-half net loss also shrank by 69 percent to $176.8 million from $578.3 million year-on-year, signaling that its accelerating revenues are translating into operating leverage.
Photo by Polina Tankilevitch on Pexels
Optimistic Growth Outlook
Encouraged by the strong results, Insmed (NASDAQ:INSM) raised its revenue growth guidance for the full-year period to a range of $1.25 billion to $1.4 billion, or an implied jump of 624 percent to 710.6 percent from the $172.7 million year-on-year,
On the other hand, its MAC lung disease therapy, Arikayce, is expected to rake in $450 million to $470 million, or a targeted 3.7 percent to 8 percent jump from the $433.8 million in the same comparable period.
Looking ahead, investors are expected to closely watch whether Brinsupri could sustain its strong momentum, while expanding Arikayce into additional markets, including Japan. The company is also awaiting a decision for brensocatib as a treatment for NCFB in Japan in the second half of 2026.
Hedge Fund Participation Softened
More broadly, hedge fund positioning notably weakened in the first quarter of the year.
Based on data from Insider Monkey, 67 hedge funds held positions in the company, down from 75 in the previous quarter.
Conviction also dropped by 13.9 percent to $7.9 billion from $9.18 billion year-on-year, signaling that investors trimmed their exposure as they reassessed the company’s risk-reward profile.
As data came prior to the second quarter results, investors will likely be expecting upcoming institutional ownership disclosures for signs that hedge funds are rebuilding positions following its stronger-than-expected commercial execution.
While we acknowledge the risk and potential of INSM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than INSM and that has 10,000% upside potential, check out our report about the cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
